Nordic News, Business and Life in Asia
A race over obesity treatments is heating up in China, as global pharmaceutical giants compete to dominate the fast-growing market for weight-loss drugs. Danish pharmaceutical company Novo Nordisk says it …
Novo Nordisk moves to launch Wegovy tablet in China Read More
The Danish pharmaceutical giant Novo Nordisk has reported encouraging results from a new diabetes and weight loss drug developed with a Chinese partner, Fierce Biotech reports. The candidate, known as …
Novo Nordisk tests China-developed drug for obesity and diabetes while competition is growing Read More
Novo Nordisk will lose patent protection for its blockbuster drug Ozempic in several major markets from Saturday. The patent expiry opens the door for other manufacturers to produce cheaper generic …
Novo Nordisk will lose patent protection on Saturday Read More
A Chinese biotechnology company, Shanghai Shiling Pharmaceutical, plans to complete clinical trials by 2028 for a weight-loss nasal spray that uses semaglutide, the same active ingredient as Danish drugmaker Novo Nordisk’s …
Chinese biotech develops semaglutide spray as Novo Nordisk patent expires in China Read More
Novo Nordisk said China’s Supreme People’s Court has upheld the validity of its semaglutide compound patent, according to a company statement issued on Saturday. China’s Supreme People’s Court thereby confirmed …
Novo Nordisk says China court upholds its semaglutide patent Read More
Danish pharmaceutical company Novo Nordisk has officially launched its once-weekly injectable weight management drug, Wegovy® (semaglutide 2.4mg), in Singapore. The treatment received regulatory approval from Singapore’s Health Sciences Authority on …
Novo Nordisk launches Wegovy in Singapore for weight management Read More
Danish pharmaceutical giant Novo Nordisk is striving to increase capacity for its blockbuster medications, Ozempic and Wegovy. To ramp up production, Novo Nordisk will focus on hiring outside of Denmark, …
Novo Nordisk expands footprint in China with recruitment shift Read More
Novo Nordisk has officially launched its weight loss medication Wegovy in China. This move opens access to over 500 million potential candidates for treatment by 2045. Regulatory approval and market …
Novo Nordisk launches Wegovy in China Read More
Novo Nordisk, the Danish pharmaceutical giant renowned for its diabetes and weight-loss medications, including the blockbuster drugs Ozempic and Wegovy, announced impressive third-quarter earnings despite challenges with production constraints. Novo …
Novo Nordisk reports strong profits despite production constraints Read More
Just as Novo Nordisk’s weight loss drug Wegovy has been allowed on the Chinese market, the company’s Chinese rivals Innovent Biologics and Eli Lilly have published news about their own …
New Chinese drug can challenge Novo Nordisk’s Wegovy in China Read More
The popular weight loss medicin Wegovy by the Danish phamaceutical firm Novo Nordisk has been approved for consumers in China. This has been confirmed by an employee at the company. …
Wegovy approved in China Read More A Chinese drugmaker applied for approval on 3 April 2024 to sell their biosimilar Ozempic drug in China. This potentially challenges the expansion plans of Novo Nordisk in China, who …
Chinese drugmaker seeks approval of Ozempic-like drug Read More
The Chinese version of the Novo Nordisk Semaglutide injection Wegovy has gotten the green light to begin clinical trials for weight loss treatment. The drug is developed by CSPC Pharmaceutical …
Chinese version of Novo Nordisk drug gets green light Read More
The Danish pharmaceutical company Novo Nordisk boosts its production in China by investing around US$ 556 million in its Chinese flagship factory in Tianjin. The sterile preparation expansion project has …
Novo Nordisk boosts drug production in China Read More
The Danish healthcare company Novo Nordisk expects China to approve their popular weight-loss drug, Wegovy, for sale this year. The company will initially focus on patient paying out-of-pocket for the …
Novo Nordisk expects China to approve Wegovy Read More
Novo Nordisk has established itself in the medicine market with patents that earn billions. Mainly due to the obesity drug Wegovy and the diabetes medicine Ozempic. Both consists of an …
Approaching patent expiration in China may threaten Novo’s billion-dollar business Read More
Danish pharmaceutical company Novo Nordisk has surpassed LVMH and is now Europe’s most valuable listed company. LVMH, the world’s biggest luxury retailer, is currently suffering due to growing concerns about …
Danish Novo Nordisk surpasses LVMH as Europe’s most valuable company Read More
Danish pharmaceutical company Novo Nordisk has achieved the highest year-on-year revenue growth by sales during the second quarter of 2023 – in comparison to the other 20 top pharmaceutical firms, …
Novo Nordisk in record growth due to obesity and diabetes drug sales Read More
Novo Nordisk’s obesity medicine Wegovy reduces the risk of heart attacks and strokes according to a highly anticipated study. People with obesity or are overweight with a history of heart …
Novo Nordisk is now second biggest firm in Europe after study finds that Wegovy cuts risk of heart attacks Read More
Danish pharmaceutical titan Novo Nordisk has applied to China’s drug regulator to widen the range of use of its diabetes medicine Ozempic. In the US Ozempic is also used as …
Novo Nordisk’s diet drug may land in China soon Read More
Danish Novo Nordisk reported Thursday, May 4, a 39% increase in first-quarter profits, due to the company’s sales of obesity treatments. From January to March, net profit reached 19.8 billion …
Novo Nordisk experience big profit rise due to obesity treatments Read More
Health Sciences Authority (HSA) in Singapore has given the green light to Wegovy. Wegovy is the weight-loss drug by Danish pharmaceutical company Novo Nordisk, that has gained huge popularity on …
Singapore approves Danish weight-loss drug Read More